ArticleProbiotics and antimicrobial proteins2025
Genomic and In Vitro Analysis of Pediococcus pentosaceus MBBL4 Implicated Its Therapeutic Use Against Mastitis Pathogens and as a Potential Probiotic.
Article in Probiotics and antimicrobial proteins, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Probiotics as Sustainable Alternatives to Mitigate Antibiotic Resistance in Bovine Mastitis Management.Probiotics and antimicrobial proteins · 2026Review
- Draft genome sequence ofMicrobiology resource announcements · 2026Article
- Genome data mining of four probioticData in brief · 2026Article
- Genomic Insights Into Antimicrobial Resistance and Virulence of Enterococcus avium Strains From Bovine Mastitis in Some Selected Dairy Farms of Bangladesh.Veterinary medicine and science · 2026Article
- Draft genome sequence and annotations of the mastitis-associated multidrug-resistantMicrobiology resource announcements · 2026Article
- Phylogenomics and gene association analysis support probiotic potential in a subset ofMicrobial genomics · 2026Article
- Draft genome sequencing of anMicrobiology resource announcements · 2026Article
- Article
- Genomic insights into multidrug resistant Escherichia coli from bovine mastitis in Bangladesh.BMC microbiology · 2025Article
- Probiotic and Technological Potential of Native Lactic Acid Bacteria Strains from High Andean Forest Bee Bread: In Vitro Study.Plant foods for human nutrition (Dordrecht, Netherlands) · 2025Article
- Probiotic potential and antimicrobial efficacy of a dairy isolate, Enterococcus faecium MBBL3.Applied microbiology and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediococcus pentosaceus has the potential to be used as probiotics and biologics amid rising trends of global antimicrobial resistance (AMR) and non-communicable diseases. This study analyzed the genome of P. pentosaceus MBBL4, isolated from healthy cow milk, to assess its probiotic properties and antimicrobial efficacy. The strain was subjected to whole genome sequencing (WGS), assembly, and annotations, alongside phylogenetic and comparative genomic analyses. Additionally, carbohydrate utilization, metabolic pathways, genomic safety, and probiotic potential of MBBL4 were assessed. Its in vitro antimicrobial efficacy against mastitis pathogens was also evaluated. The WGS analysis uncovered many important probiotic traits in MBBL4. Phylogenetic analysis demonstrated a close genetic link with other 15 P. pentosaceus strains, sharing more than 99% of core genes within the pan-genome matrix. MBBL4 demonstrated extensive range of carbohydrate metabolism activity, supported by the presence of several genes encoded enzymes, including a complete elucidated lactose metabolism pathway along with 28 additional metabolic pathway modules. Notably, its genome contains regions associated with gallic acid metabolism and related genes. MBBL4 also harbored genes encoding immunity proteins like enterocin A and lactococcin, and antimicrobial compounds including penocin A, lysozymes, laccase, colicin V, and viguiepinol. Comparative analysis with other probiotic strains revealed seven novel exopolysaccharide biosynthesis proteins and one biofilm-related protein. Moreover, MBBL4 remained sensitive to 90% of the tested antibiotics and carried only a single lincosamide resistance gene (lnuA). It effectively inhibited the growth of two important bovine mastitis pathogens, Staphylococcus aureus D4C4 and Escherichia coli G1C5. These results, along with its low pathogenicity score, support the safety profile of MBBL4 and highlight its potential as bioactive natural therapeutic for mastitis and a promising probiotic candidate.
Indexed as
Identifiers
39976902What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.